Timeline of incretin therapeutics: difference between revisions
Diff·revision 10 → 11·14:39, 24 Dec 2024
Difference between revision 10 and revision 11 of Timeline of incretin therapeutics. 8 lines changed; the page grew by 319 bytes.
| Revision 10 — 18:22, 8 Dec 2024 Compounding_Cate (talk) add the receptor targets to the lead sentence 2,813 bytes +461 | Revision 11 — 14:39, 24 Dec 2024 SurvodutideSaff (talk) expand §Second generation and beyond 3,132 bytes +319 | ||
|---|---|---|---|
| 37 | | 2016 | [[LEADER trial]] reports cardiovascular benefit | | 37 | | 2016 | [[LEADER trial]] reports cardiovascular benefit | |
| 38 | 38 | ||
| + | 39 | The 2016 result changed the framing of the class from glucose-lowering to outcome-modifying, and it did so in a period when cardiovascular outcome trials were being run principally to exclude harm.{{r|drucker2018}} | |
| + | 40 | ||
| 39 | == References == | 41 | == References == |
| 40 | {{reflist}} | 42 | {{reflist}} |
| ⋮ | ⋮ | ||
| 42 | <ref name="holst2007">Holst JJ. "The physiology of glucagon-like peptide 1." ''Physiological Reviews'' 87(4):1409–1439 (2007). PMID 17928588.</ref> | 44 | <ref name="holst2007">Holst JJ. "The physiology of glucagon-like peptide 1." ''Physiological Reviews'' 87(4):1409–1439 (2007). PMID 17928588.</ref> |
| 43 | <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> | 45 | <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> |
| + | 46 | ||
| + | 47 | == See also == | |
| + | 48 | * [[Incretin effect]] | |
| + | 49 | * [[GLP-1 receptor agonist]] | |
| + | 50 | * [[Semaglutide]] | |
| + | 51 | * [[Tirzepatide]] | |
| 44 | 52 | ||
| 45 | {{DEFAULTSORT:Timeline of incretin therapeutics}} | 53 | {{DEFAULTSORT:Timeline of incretin therapeutics}} |